NO20080278L - Prodrugs av A2B-adenosinreseptorantagonister - Google Patents

Prodrugs av A2B-adenosinreseptorantagonister

Info

Publication number
NO20080278L
NO20080278L NO20080278A NO20080278A NO20080278L NO 20080278 L NO20080278 L NO 20080278L NO 20080278 A NO20080278 A NO 20080278A NO 20080278 A NO20080278 A NO 20080278A NO 20080278 L NO20080278 L NO 20080278L
Authority
NO
Norway
Prior art keywords
receptor antagonists
adenosine receptor
prodrugs
mammals
pro
Prior art date
Application number
NO20080278A
Other languages
English (en)
Norwegian (no)
Inventor
Dmitry Koltun
Jeff Zablocki
Rao Kalla
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20080278L publication Critical patent/NO20080278L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20080278A 2005-06-16 2008-01-15 Prodrugs av A2B-adenosinreseptorantagonister NO20080278L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69140805P 2005-06-16 2005-06-16
PCT/US2006/023167 WO2006138376A1 (en) 2005-06-16 2006-06-14 Prodrugs of a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
NO20080278L true NO20080278L (no) 2008-02-28

Family

ID=37215988

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080278A NO20080278L (no) 2005-06-16 2008-01-15 Prodrugs av A2B-adenosinreseptorantagonister

Country Status (14)

Country Link
US (3) US7625881B2 (enExample)
EP (2) EP2301937A1 (enExample)
JP (1) JP5044823B2 (enExample)
KR (1) KR20080016645A (enExample)
CN (1) CN101198608B (enExample)
AU (1) AU2006259411B2 (enExample)
CA (1) CA2612344A1 (enExample)
IL (1) IL188103A0 (enExample)
MX (1) MX2007015909A (enExample)
NO (1) NO20080278L (enExample)
NZ (1) NZ564326A (enExample)
RU (2) RU2415858C2 (enExample)
WO (1) WO2006138376A1 (enExample)
ZA (1) ZA200710878B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
EP1658291B1 (en) * 2003-08-25 2013-10-02 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
EP2311462A1 (en) 2004-10-15 2011-04-20 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
CA2612344A1 (en) 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
CA2646333C (en) * 2006-03-17 2014-06-17 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
WO2009088518A1 (en) * 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
EP2521545B1 (en) * 2010-01-07 2019-11-27 Alkermes Pharma Ireland Limited Prodrugs of heteroaromatic compounds
KR20130088834A (ko) * 2010-06-30 2013-08-08 길리애드 사이언시즈, 인코포레이티드 폐 고혈압의 치료를 위한 ａ２ｂ 아데노신 수용체 길항제의 용도
EP2616470B1 (en) 2010-09-13 2016-10-12 Advinus Therapeutics Limited Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
US9359376B2 (en) * 2011-04-08 2016-06-07 Sphaera Pharma Pte. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
SI2859009T1 (sl) 2012-06-08 2017-12-29 Gilead Sciences, Inc. Makrociklični inhibitorji flaviviridae virusov
IN2014MN02652A (enExample) 2012-06-08 2015-08-21 Gilead Sciences Inc
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
KR102671166B1 (ko) * 2015-12-14 2024-05-31 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 3,5-디페닐-디아졸 화합물의 수용성 유도체
JP7849948B2 (ja) * 2018-03-05 2026-04-22 テオン セラピューティクス，インク． アデノシン受容体アンタゴニストおよびその使用
JP7156154B2 (ja) * 2019-04-18 2022-10-19 株式会社島津製作所 培地処理システム及び培地処理方法
TW202327612A (zh) * 2021-09-10 2023-07-16 美商天恩治療有限公司 使用腺苷受體拮抗劑之改良療法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
TW252044B (enExample) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6815446B1 (en) * 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
US6894021B2 (en) * 2000-02-17 2005-05-17 Cv Therapeutics, Inc. Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
US6387913B1 (en) 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US20030235555A1 (en) 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) * 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
AU2002359365B2 (en) 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
KR20040068317A (ko) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
JP2006518390A (ja) * 2003-02-19 2006-08-10 エンダシア，インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
WO2004106337A1 (en) * 2003-05-06 2004-12-09 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
EP1658291B1 (en) * 2003-08-25 2013-10-02 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
US7449473B2 (en) * 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists
PL1789053T3 (pl) * 2004-09-01 2012-12-31 Gilead Sciences Inc Sposób gojenia się rany wykorzystujący antagonistów receptora adenozynowego A2B
EP2311462A1 (en) * 2004-10-15 2011-04-20 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
CA2612344A1 (en) 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
CA2646333C (en) * 2006-03-17 2014-06-17 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
US8338593B2 (en) * 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
JP5460690B2 (ja) * 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物

Also Published As

Publication number Publication date
EP1891070A1 (en) 2008-02-27
RU2010150615A (ru) 2012-06-20
US20110160162A1 (en) 2011-06-30
EP2301937A1 (en) 2011-03-30
US20100056538A1 (en) 2010-03-04
MX2007015909A (es) 2008-03-06
RU2007146669A (ru) 2009-06-20
US7625881B2 (en) 2009-12-01
AU2006259411A1 (en) 2006-12-28
WO2006138376A1 (en) 2006-12-28
NZ564326A (en) 2010-01-29
ZA200710878B (en) 2009-05-27
AU2006259411B2 (en) 2012-03-22
CN101198608B (zh) 2011-04-27
US20060293283A1 (en) 2006-12-28
KR20080016645A (ko) 2008-02-21
CA2612344A1 (en) 2006-12-28
JP5044823B2 (ja) 2012-10-10
US8143249B2 (en) 2012-03-27
RU2415858C2 (ru) 2011-04-10
JP2008543860A (ja) 2008-12-04
IL188103A0 (en) 2008-03-20
CN101198608A (zh) 2008-06-11

Similar Documents

Publication Publication Date Title
PL3424932T3 (pl) Boronoftalidy do zastosowania terapeutycznego
SI1827441T1 (sl) Kombinacije za zdravljenje bolezni, povezanih s celično proliferacijo
HUE038588T2 (hu) IL-22 mikrobiális rendellenességek kezelésében történõ alkalmazásra
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
DE112006002352A5 (de) Stabförmiger Körper
HN2009000018A (es) Inhibidores de tirosina quinasa
ATE496924T1 (de) Prodrugs von 5-amino-3-(3'-deoxy-beta-d- ribofuranosyl)-thiazolä4,5-düpyrimidin-2,7-dion
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
IL195900A0 (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
DE502006009211D1 (de) Möbel
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
NO20081923L (no) Adenosin A2a-reseptorantagonister for behandling av ekstra-pyramidalt syndrom og andre bevegelsesforstyrrelser
IS8575A (is) 3-ß-D-ríbófúranósýlþíasóló [4,5-d]pýridímínnúkleósíð og notkun þeirra
BRPI0821026A2 (pt) Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
DK2185561T3 (da) Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf
ZA200803236B (en) Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders
DK1765844T3 (da) Purin-nukleotidderivater
BRPI0511124A (pt) pró-drogas de inibidores de erk proteìna cinase de pirrolilpirimidina
ATE556080T1 (de) Purinderivat
BRPI0714307A2 (pt) Uso de benzamidas trifluormetil-substituídas no tratamento de distúrbios neurológicos
DK2059521T3 (da) Pyrazolo[1,5-A]pyrimidiner, fremgangsmåder, anvendelse og sammensætninger
EP2039392A4 (en) DEVICE FOR PHYSIOTHERAPY TREATMENT OF DISEASES OF VARIOUS AITIOLOGIES
FR2866223B1 (fr) Article de literie
SE0500053D0 (sv) Therapeutic agents 1

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application